Genomma Lab Internacional Stock Return On Equity
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company Return On Equity Analysis
Genomma Lab's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Genomma Lab Return On Equity | 0.13 |
Most of Genomma Lab's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genomma Lab Internacional is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Genomma Lab Internacional has a Return On Equity of 0.1264. This is 100.53% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 140.77% lower than that of the firm.
Genomma Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in return on equity category among its peers.
Genomma Fundamentals
Return On Equity | 0.13 | |||
Return On Asset | 0.0921 | |||
Profit Margin | 0.08 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 1.09 B | |||
Shares Outstanding | 1 B | |||
Shares Owned By Insiders | 29.00 % | |||
Shares Owned By Institutions | 29.10 % | |||
Price To Earning | 11.09 X | |||
Price To Book | 1.38 X | |||
Price To Sales | 0.05 X | |||
Revenue | 15.49 B | |||
Gross Profit | 9.56 B | |||
EBITDA | 2.84 B | |||
Net Income | 1.31 B | |||
Cash And Equivalents | 1.3 B | |||
Cash Per Share | 1.30 X | |||
Total Debt | 3.83 B | |||
Debt To Equity | 0.51 % | |||
Current Ratio | 1.67 X | |||
Book Value Per Share | 10.98 X | |||
Cash Flow From Operations | 1.47 B | |||
Earnings Per Share | 0.07 X | |||
Number Of Employees | 2.3 K | |||
Beta | 0.53 | |||
Market Capitalization | 973.77 M | |||
Total Asset | 21.54 B | |||
Annual Yield | 0.05 % | |||
Net Asset | 21.54 B | |||
Last Dividend Paid | 0.38 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Stocks Directory Find actively traded stocks across global markets |